摘要
目的观察舒利迭吸入剂对慢性阻塞性肺疾病(COPD)稳定期患者病变程度及生活质量的影响。方法 64例COPD稳定期患者在戒烟及对症治疗基础上给予舒利迭吸入剂治疗,每次1吸,2次/d,连续治疗3个月,比较治疗前后肺功能指标、病变程度及生活质量的变化。结果治疗后,患者肺功能指标用力肺活量(FVC)、第1秒用力呼气量(FEV1)、第1秒用力呼气量与用力肺活量比值(FEV1/FVC)、最大呼气中段平均流速(MMEF)及呼气峰值流速(PEF)较治疗前均显著增高(P<0.05);病变程度较治疗前也得到明显改善(P<0.01);欧洲五维健康量表(EQ-5D)中的视觉模拟评分(EQ-VAS)由治疗前的(56.75±22.47)分增至治疗后的(67.63±25.12)分,EQ-5D指数评分(EQ-5D)从治疗前的(0.58±0.22)分增至治疗后的(0.71±0.26)分,治疗前后EQ-VAS和EQ-5D指数评分比较,差异均有统计学意义(P<0.05)。结论舒利迭吸入剂治疗COPD稳定期患者疗效确切,能有效改善肺功能,纠正或缓解病变程度,从而有效提高患者的生活质量。
Objective To investigate the effect of Seretide on disease severity and quality of life of Patients with stable chronic obstructive pulmonary disease （COPD）.Methods 64 COPD patients at stable stage were treated with Seretide for three months on the basis of conventional treatment. The lung function, the disease severity and scores for the EuroQol five-dimension questionnaire （EQ-5D）of patients were measured and compared between pre-and post-treatment. Results The pulmonary function including FVC, FEV1, FEV1/FVC, MMEF, PEF and disease severity of COPD patients at stable stage significantly differed from the baseline were improved （P〈0.01）.There was significant difference between pre-and post-treatment in EQ-5D scores （P〈0.05）.Conclusion Seretide is effective for the promotion of the pulmonary function and the quality of life of the COPD patients at the stable stage.
出处
《基层医学论坛》
2012年第16期2056-2058,共3页
The Medical Forum
关键词
慢性阻塞性肺疾病舒利迭肺功能
生活质量
Chronic obstructive pulmonary diseases Seretide Lung function Quality of life
